ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

HCID 107526
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
19030-38-7
標準SMILES
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChIKey
GZCGUPFRVQAUEE-SLPGGIOYSA-N
分子式
C6H12O6
平均分子量
180.16 g/mol
単同位体質量
180.0633881

概要

Aldehydo-D-glucose is the open chain form of D-glucose. It is a D-glucose and an aldehydo-glucose. It is an enantiomer of an aldehydo-L-glucose.

名称と識別子

優先名称
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal
IUPAC
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal
英語名
D-Glucose-UL-14C
分子式
C6H12O6
分子量
180.16

名称と別名

(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanalRefChem:934733GlyTouCan:G59743JOG59743JOD-(+)-GlucoseDL-Glucosealdehydo-D-glucose58367-01-4Glucose [JAN]DTXSID4048729815-92-9Glucose, liquid
名称をさらに表示
D-Glucose-UL-14CD-[U-14C]GLUCOSED-GLUCOSE, [U-14C]GLUCOSE, D-[14C(U)]-D-Glucose, labeled with carbon-14D-GLUCOSE-UL-14C 2-10 MCI PER MMOL*AQUEO US SOLUTION
Glucopur(14C)-Glucose(14C)D-Glucose(C13)D-Glucose(U-14C)GlucoseGlucose (C-13)Glucose (C-14)D-(U-14C)Glucose

データベース識別子

CAS
19030-38-7、28823-03-2、50-99-7、58367-01-4、8027-56-3、815-92-9
PubChem CID
107526
DTXSID
DTXSID4048729
ChEMBL
CHEMBL448805
ChEBI
CHEBI:42758
UNII
5SL0G7R0OK
Nikkaji
J4.109B

物性

構造計算による物性

XLogP
-2.9
極性表面積
118 Ų
水素結合供与体数
5
水素結合受容体数
6
回転可能結合数
5
重原子数
12
形式電荷
0
複雑度
138

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
SpringerMaterials PropertiesChemical shift
LogP-1.88
SolubilitySoluble

物理化学的性質

闪点
20 °C · 20 °C
貯蔵温度
2 · 2-8°C
外見
水溶液

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Regulatory Information · 2 件

Chemical: Liquid glucose

Liquid glucose: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Liquid glucose: Human health tier I assessment

安全データ

wgk
3
ridadr
UN 2910 7
risk_code
11-36/37/38
hazard_code
R,F,Xi
safety_code
16-26-36

化学と産業

薬理情報

Pharmacodynamics · 1 件

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.

Mechanism of Action · 1 件

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity.

Biological Half-Life · 1 件

The approximate half-life is 14.3 minutes following intravenous infusion. Gut glucose half-life was markedly higher in females (79 ± 2 min) than in males (65 ± 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).

Metabolism/Metabolites · 1 件

Glucose can undergo aerobic oxidation in conjunction with the synthesis of energy molecules. Glycolysis is the initial stage of glucose metabolism where one glucose molecule is degraded into two molecules of pyruvate via substrate-level phosphorylation. These products are transported to the mitochondria where they are further oxidized into oxygen and carbon dioxide.

Absorption, Distribution and Excretion · 4 件

Polysaccharides can be broken down into smaller units by pancreatic and intestinal glycosidases or intestinal flora. Sodium-dependent glucose transporter SGLT1 and GLUT2 (SLC2A2) play predominant roles in intestinal transport of glucose into the circulation. SGLT1 is located in the apical membrane of the intestinal wall while GLUT2 is located in the basolateral membrane, but it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of glucose by facilitated diffusion. Oral preparation of glucose reaches the peak concentration within 40 minutes and the intravenous infusions display 100% bioavailability.

Glucose can be renally excreted.

The mean volume of distribution after intravenous infusion is 10.6L.

The mean metabolic clearance rate of glucose (MCR) for the 10 subjects studied at the higher insulin level was 2.27 ± 0.37 ml/kg/min at euglycemia and fell to 1.51±0.21 ml/kg/ at hyperglycemia. The mean MCR for the six subjects studied at the lower insulin level was 1.91 ± 0.31 ml/kg/min at euglycemia.

関連反応

1,051 件
反応記録を作成
HRID 1430 の反応式
HRID 1430反応物として
HRID 1432 の反応式
HRID 1432生成物として
HRID 1925 の反応式
HRID 1925生成物として
HRID 1958 の反応式
HRID 1958反応物として
HRID 10125 の反応式
HRID 10125反応物として
HRID 10130 の反応式
HRID 10130反応物として
HRID 10131 の反応式
HRID 10131反応物として
HRID 12001 の反応式
HRID 12001触媒として反応物として
前へ1 / 132 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート